ACU193 was identified as Acumen’s lead development candidate based on its preference for toxic amyloid-beta oligomers (Aβo). ACU 193 is a humanized, affinity matured, IgG2m4 subclass monoclonal antibody (mAb) and is positioned as potential best-in-class Alzheimer’s immunotherapy based on its potential to 'thread the needle' for superior clinical effects by targeting Aβo without an ARIA-E inflammation liability.

Based on preclinical efficacy data we expect ACU193 to provide Alzheimer’s patients with meaningful clinical benefit with an acceptable safety profile.

Screen Shot 2019-07-28 at 2.04.02 PM.png